Bibliographic Info
GuidelineWHO consolidated guidelines on drug-resistant tuberculosis treatment
Year of Publication2019
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
Pyrazinamide may be included in the treatment of multidrug-resistant TB or isoniazid-resistant, rifampicin-resistant TB patients on longer regimens
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
Year2020
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year2022
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization